LLY Eli Lilly and Co
- 833.450
- +13.110+1.60%
Eli Lilly and Co News
QurAlis Grants Lilly Exclusive Global License For QRL-204, A Precision Therapy That Restores UNC13A Function In ALS And FTD
QRL-204 is a splice-switching ASO generated through QurAlis' FlexASO Platform; represents Lilly's first program targeting UNC13A in ALS and FTDParties to also collaborate to leverage QurAlis' ALS and
Eli Lilly Granted Exclusive License to QurAlis Candidate for Neurodegenerative Diseases
Eli Lilly and Co's Options: A Look at What the Big Money Is Thinking
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co.Looking at options history for Eli Lilly and Co (NYSE:LLY) we detected 22 trades.If we consider the speci
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
While Dow Inc. futures are slightly down, IT and high tech stocks are being bought. Gamestop is rapidly rising in after-hours trading = US Stocks.
While Dow futures are slightly down in the US stock index futures market, buying is expanding in IT and high-tech stocks, causing the S&P 500 and NASDAQ 100 to rise today.
Structure Therapeutics' Stock Jumps on Weight-loss-pill Trial Results
By Eleanor Laise GLP-1 drugs in pill form could improve the medications' accessibility and affordability, analysts say Structure Therapeutics Inc.'s American depositary receipts (GPCR) gained more t
Express News | Quralis: Eligible for Future Milestone Payments of up to $577 Mln & Tiered Royalties on Net Sales
Express News | Quralis: Grants Eli Lilly Exclusive License for Qrl-204, Potential Precision Therapy for Restoration of Unc13a Function in ALS & Ftd
Express News | Quralis: License Granted in Exchange for Upfront Payment of $45 Mln, Plus Additional Equity Investment
Express News | Reported Saturday, Eli Lilly's Olomorasib Presented Updated Data From The Phase 1/2 Study For KRAS G12C-Mutant Solid Tumors At ASCO 2024
Stocks Most Shunned by Hedge Funds and Mutual Funds
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
FDA Oncology Chief Says International Clinical Trials Should Be Priority
Express News | Eli Lilly : Data Demonstrated Promising Monotherapy Activity With Olomorasib Across a Range of Kras G12C-Mutant Solid Tumors
Updated Data From the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients...
Updated Data From the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO Annual Meeting
Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with p
Express News | NYSE Order Imbalance 144589.0 Shares on Buy Side
Form 144 | Eli Lilly and Co(LLY.US) 10% Stockholder Proposes to Sell 175.24 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 31, $Eli Lilly and Co(LLY.US)$ 10% Stockholder LILLY ENDOWMENT INC intends to sell 215K shares of its common stock on May 31, with a total market value of approximately $17
Top Research Reports for Eli Lilly, T-Mobile & BHP
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry o
Analysis
Price Target
No Data
